dpp-4 inhibitors vs. glp-1 agonist GLP 1 Receptor Agonists and DPP 4 Mechanism of Action DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes

It was developed by Sanofi Aventis under a license from Zealand Pharma

M.RyanD

[DOI] [PubMed] [Google Scholar] 918.Bech E.M., Voldum-Clausen K., Pedersen S.L., Fabricius K., Rudkjaer L.C.B., Hansen H.H

Pratley RE
